4-[Amino(2,4-dimethoxyphenyl)methyl]phenol | 120404-63-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[Amino(2,4-dimethoxyphenyl)methyl]phenol
• 英文别名: 4-[amino-(2,4-dimethoxyphenyl)methyl]phenol
• CAS: 120404-63-9
• 化学式: C₁₅H₁₇NO₃
• 分子量: 259.3
• InChiKey: XMRJBDQTEFAUIH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  64.7
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides
  申请人：Robinson Andrea

  公开号：US20070197429A1

  公开（公告）日：2007-08-23

  According to the present invention, there is provided a range of new conotoxin derivatives and methods for synthesizing these analogues and other intramolecular dicarba bridge-containing peptides, including dicarba-disulfide bridge-containing peptides.

  根据本发明，提供了一系列新的芋螺毒素衍生物以及合成这些类似物和其他含内分子二碳桥肽的方法，包括含二碳-二硫桥肽。
• Derivatives of structurally modified VIP and pharmaceutical compositions containing them
  申请人：YEDA RESEARCH AND DEVELOPMENT CO. LTD.

  公开号：EP0540969A2

  公开（公告）日：1993-05-12

  There are provided novel compounds for the treatment of male impotence. The compounds are derived from vasoactive intestinal peptide (VIP) and VIP₇₋₂₈ and VIP₁₆₋₂₈ fragments in which the natural amino acid sequence is modified by replacement of any of the 5, 17 and 19 amino acid residues by other natural or non-natural amino acids, and they bear at least one terminal lipophilic group. The modified VIP sequences and fragments are prepared by conventional peptide chain assembling methods. The novel compounds and compositions containing them are suitable for transdermal application.

  本文提供了用于治疗男性阳痿的新型化合物。这些化合物来源于血管活性肠肽（VIP）、VIP₇₋₂₈和 VIP₁₆₋₂₈ 片段，其中的天然氨基酸序列通过用其他天然或非天然氨基酸替换 5、17 和 19 个氨基酸残基中的任何一个进行了修饰，并且它们带有至少一个末端亲脂基团。 修饰的 VIP 序列和片段是通过传统的肽链组装方法制备的。 这些新型化合物和含有它们的组合物适用于透皮应用。
• Use of vip, analogues and fragments thereof for the treatment of neurodegenerative diseases
  申请人：YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD.

  公开号：EP0620008A1

  公开（公告）日：1994-10-19

  Use of a peptide selected from the group consisting of: (i) vasoactive intestinal peptide (VIP); (ii) analogues of vasoactive intestinal peptide (VIP) in which one or more amino acids has been replaced, added or deleted without substantially altering the biological properties of the parent peptide (iii) a conjugate being a peptide according to either of (i) and (ii) coupled to a lipophilic moiety; (iv) a physiologically active fragment of (i), (ii) and (iii); and (v) a functional derivative of any of (i), (ii), (iii) and (iv) for the preparation of a medicament for the treatment of neurodegenerative disease.

  使用选自以下组成的组的肽 (i) 血管活性肠肽（VIP）； (ii) 血管活性肠肽（VIP）的类似物，其中一个或多个氨基酸被替换、添加或 删除，但并不严重改变母肽的生物特性 (iii) 由(i)和(ii)中任何一项所述的肽与亲脂分子结合而成的共轭物； (iv) (i)、(ii)和(iii)的生理活性片段；以及 (v) (i)、(ii)、(iii)和(iv)中任何一种的功能衍生物，用于制备治疗神经退行性疾病的药物。
• Side-chain protected oligopeptide fragment condensation using subtilisins in organic solvents
  申请人：Enzypep B.V.

  公开号：EP2634193A1

  公开（公告）日：2013-09-04

  Method for enzymatically synthesising an oligopeptide, comprising the coupling of an (optionally N-protected) protected oligopeptide ester with an (optionally C-protected) protected oligopeptide nucleophile in an organic solvent or an organic solvent mixture having a water content of 0.1 vol% or less, by a subtilisin in any possible form.

  酶法合成低聚肽的方法，包括在有机溶剂或含水量不超过 0.1 Vol% 的有机溶剂混合物中，用任何可能形式的枯草蛋白将（任选 N 保护的）受保护的低聚肽酯与（任选 C 保护的）受保护的低聚肽亲核物偶联。
• Chemical capture reagent
  申请人：——

  公开号：US20040242854A1

  公开（公告）日：2004-12-02

  Disclosed is a capture reagent having Formula I: PRG-L-X-carrier  (I) wherein: PRG is a peptide or protein reactive group; L is a linker group comprising a stable isotopic detectable label moiety; and X is a cleavable group. Also disclosed is a method for selective labelling and purification of proteins and peptides comprising using a capture reagent of Formula I.

  公开了一种具有式 I 的捕获试剂： PRG-L-X-载体(I) 其中 PRG 是肽或蛋白质活性基团； L 是包含稳定同位素可检测标记分子的连接基团；以及 X 是可裂解基团。 还公开了一种蛋白质和肽的选择性标记和纯化方法，包括使用式 I 的捕获试剂。